Status:
UNKNOWN
COVID-19 Vaccination in Patients With Rheumatic Diseases
Lead Sponsor:
Sociedad Argentina de Reumatologia
Conditions:
Rheumatic Diseases
Eligibility:
All Genders
18+ years
Brief Summary
The Argentine Society of Rheumatology (SAR) set out to develop a national register of patients with rheumatic diseases who have received a SARS-CoV-2 vaccine in order to assess their efficacy and safe...
Detailed Description
This is an observational, longitudinal, multicenter study, including patients with rheumatic diseases who have been vaccinated for COVID-19 in Argentine or any country. Patients will be followed for 1...
Eligibility Criteria
Inclusion
- Patients ≥ 18 years of age.
- Diagnosis of rheumatic disease treated or not with immunosuppressive agents
- Patients who have received at least one dose of a SARS-CoV-2 vaccine
- Signature of informed consent.
Exclusion
- Patients who express their desire not to participate in the study or who are unable to give their informed consent.
Key Trial Info
Start Date :
July 1 2021
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 31 2023
Estimated Enrollment :
3000 Patients enrolled
Trial Details
Trial ID
NCT04845997
Start Date
July 1 2021
End Date
December 31 2023
Last Update
February 1 2023
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Sociedad Argentina de Reumatología
Buenos Aires, Buenos Aires F.D., Argentina, 1022
2
Sociedad Argentina de Reumatologia
Buenos Aires, Argentina, 1022